#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma byKathleen Lau July 1, 2021 0
#VisualAbstract Dexamethasone improved isatuximab efficacy in patients with relapsed/refractory multiple myeloma byKathleen Lau March 26, 2021 0
#VisualAbstract MRCN-003/CCTGMYX.1: Weekly carfilzomib, cyclophosphamide, and dexamethasone may be a safe and effective option for patients with relapsed/refractory multiple myeloma byKathleen Lau March 19, 2021 0
#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma byKathleen Lau March 4, 2021 0
Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma byKathleen Lau February 5, 2021 0
#VisualAbstract Renal Toxicity Associated with Carfilzomib in Multiple Myeloma Patients byKathleen Lau December 3, 2020 0
